<DOC>
	<DOCNO>NCT02685306</DOCNO>
	<brief_summary>The primary purpose research study see whether add bavituximab ( investigational drug ) standard chemotherapy drug taxane , improve result treatment early- stage Triple Negative Breast Cancer follow Standard- of- Care surgery</brief_summary>
	<brief_title>A Study Neoadjuvant Paclitaxel Combination With Bavituximab Early- Stage Triple- Negative Breast Cancer</brief_title>
	<detailed_description>This open-label randomized trial patient early- stage Triple Negative Breast Cancer . Patients treat either paciltaxel alone paclitaxel bavituximab . Paclitaxel give weekly , bavituximab give weekly . All therapy continue twelve dos treatment follow standard care definitive surgical resection .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Written inform consent obtain prior screen . 2 . Target Population 1 . Female male least 18 year age . 2 . Invasive breast cancer confirm pathology evaluation core biopsy . 3 . Earlystage TNBC accord American Joint Committee Cancer ( AJCC ) Staging Manual Clinical Stage I ( T1c , &gt; 1.5 cm ) , Stage II Stage III invasive breast cancer . 4 . Tumors must ER/PgR status negative ( IHC &lt; 1 % ) lack HER2/neu overexpression amplification measure local hospital pathology laboratory ( IHC +/ fluorescence situ hybridization ( FISH ) IHC &lt; 3+ , FISH &lt; 2.2 ) describe NCCN Guidelines . 5 . Patient must consent minimum 1 tumorcontaining formalin fix paraffin embed core ( archival tissue ) baseline research biopsy . 3 . Eastern Cooperative Oncology Group Performance Status 0 1 . 4 . Adequate hematologic function ( absolute neutrophil count ≥ 1,500 cells/µL ; hemoglobin &gt; 9 g/dL , platelet &gt; 100,000/µL. ) . 5 . Adequate renal function ( serum creatinine ≤ 1.5 mg/dL calculate creatinine clearance ≥ 60 mL/min use CockcroftGault equation ) . 6 . Adequate hepatic function : total bilirubin ≤ upper limit normal ( ULN ) , serum albumin ≥≥ 3.0 g/dL , alanine aminotransferase aspartate aminotransferase ≤ 1.5 x ULN . 7 . Prothrombin time and/or international normalize ratio ( INR ) ≤ 1.5 x ULN activate partial thromboplastin time ≤ 1.5 x ULN , patient anticoagulant therapy . 8 . Female patient must negative serum human chorionic gonadotropin test within 1 week Day 1 ( pregnancy test require patient bilateral oophorectomy and/or hysterectomy patient &gt; 1 year postmenopausal 9 . Women childbearing potential must avoid become pregnant men must avoid father child 3 month end study treatment . 1 . Surgically unresectable , inflammatory , metastatic breast cancer . 2 . Any prior treatment current breast cancer include chemotherapy , hormonal therapy , radiation , experimental therapy . 3 . Known history bleed diathesis coagulopathy ( e.g. , von Willebrand disease hemophilia ) . 4 . Clinically significant bleeding , gross hematuria , gastrointestinal bleeding screening ( clinically significant bleeding occur within 6 month screen , cause identify adequately treat [ e.g. , cystitis , ulcer ] , exclusion criterion apply . Minor biopsyrelated bleed last &lt; 24 hour resolve least 1 week Day 1 allow . 5 . Thromboembolic event ( e.g. , deep vein thrombosis , pulmonary embolism , arterial thrombosis ) occur within 6 month screen . 6 . Uncontrolled intercurrent disease ( e.g. , diabetes , hypertension , thyroid disease , active infection ) . 7 . Autoimmune disease require treatment chronic systemic immunosuppressive therapy . Prior allotransplantation . 8 . History hypersensitivity excipients paclitaxel ( e.g. , Cremaphor ) . 9 . Has active infection require systemic therapy . 10 . Major surgery within 4 week prior Day 1 11 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 12 . Investigational therapy within 28 day prior Day 1 . 13 . Is pregnant breastfeeding , expect conceive within project duration trial . 14 . Has know history human immunodeficiency virus ( HIV ) ( HIV1/2 antibody ) active hepatitis B ( e.g. , HBsAg reactive ) hepatitis C ( e.g. , hepatitis C virus RNA [ qualitative ] detect .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>